Lancashire and South Cumbria
Formulary
Formulary
13 Skin
|
Dermatology prescribing may require use of expensive unlicensed Specials Recommended by the British Association of Dermatologists for Skin Disease |
|
Several medicines in the skin chapter are available for purchase over the counter and may be appropriate for self care. Please consult the local OTC policy for more details. LSCMMG: Over The Counter (OTC) Items That Should Not Be Routinely Prescribed In Primary Care Policy |
13-06-02 Hormone treatment for acne
| Co-Cyprindiol |
|
Formulary
|
Tablets cyproterone 2mg / ethinylestradiol 35 micrograms |
 MHRA: Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive MHRA: Cyproterone acetate: new advice to minimise risk of meningioma |
|
Links
- British Association of Dermatologists guideline on safe use of isotretinoin, 2010
Lancashire and South Cumbria Infant Feeding Network - Diagnosis and Management of Milk Allergy and Intolerance Guideline- LSCMMG: Brimonidine Tartrate (Mirvaso) 3mg/g Gel NMR
- LSCMMG: Inflammatory Bowel Disease: High Cost Drugs Commissioning Pathway
- LSCMMG: Ivermectin cream 10mg/g (Soolantra®) NMR
- LSCMMG: Primary Care Constipation Guidelines
- MHRA Drug Safety Update Aug 2020: Isotretinoin (Roaccutane): reminder of important risks and precautions
- MHRA Drug Safety Update Dec 2014: Isotretinoin (Roaccutane): reminder of possible risk of psychiatric disorders
- MHRA Drug Safety Update July 2021: Oral retinoid medicines (isotretinoin, alitretinoin, and acitretin): temporary monitoring advice during coronavirus (COVID-19) pandemic
- MHRA Drug Safety Update Oct 2017: Isotretinoin (Roaccutane): rare reports of erectile dysfunction and decreased libido
- MHRA update on risk of serious skin reactions (Sept 2010)
- MHRA: Antiepileptic drugs in pregnancy: updated advice following comprehensive safety review
- MHRA: Brimonidine gel (Mirvaso): risk of exacerbation of rosacea
- MHRA: Brimonidine gel (Mirvaso): risk of systemic cardiovascular effects; not to be applied to damaged skin
- MHRA: Cyproterone acetate with ethinylestradiol (co-cyprindiol): balance of benefits and risks remains positive
- MHRA: Cyproterone acetate: new advice to minimise risk of meningioma
- MHRA: Erythromycin: caution required due to cardiac risks (QT interval prolongation); drug interaction with rivaroxaban
- MHRA: Erythromycin: update on known risk of infantile hypertrophic pyloric stenosis
- MHRA: Isotretinoin – updates to prescribing guidance and survey of services
- MHRA: Isotretinoin (Roaccutane▼): introduction of new safety measures, including additional oversight of the initiation of treatment for patients under 18 years of age
- MHRA: Isotretinoin: risk of serious skin reactions
- MHRA: Oral retinoid medicines▼: revised and simplified pregnancy prevention educational materials for healthcare professionals and women
- MHRA: Oral retinoids pregnancy prevention reminder
- MHRA: Oral retinoids: pregnancy prevention—reminder of measures to minimise teratogenic risk
- MHRA: updated prescribing information regarding risks and benefits (July 2013)
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE new medicine summary: Inflammatory lesions of papulopustular rosacea: ivermectin 10 mg/g cream
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people